New Antidepressant Brintellix OKd

Tuesday, 01 Oct 2013 11:29 AM

 

  Comment  |
   Contact  |
  Print  
|  A   A  
  Copy Shortlink
The U.S. Food and Drug Administration approved Lundbeck's antidepressant Brintellix to treat adults with major depressive disorder.

The drug, which Lundbeck will co-market with Japanese partner Takeda Pharmaceutical Co Ltd, will be available in four doses.
 
Brintellix, like other antidepressants, will carry a boxed warning alerting patients and doctors to an increased risk of suicidal thoughts and behavior in children, adolescents and young adults aged 18-24 during initial treatment.
 
The most common side effects reported by patients taking the drug — generically known as vortioxetine — include nausea, constipation and vomiting.

Major depressive disorder is characterized by mood changes that may interfere with a person's ability to carry out to day-to-day activities. Symptoms also include increased fatigue and feelings of guilt or worthlessness.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact  |
  Print  
  Copy Shortlink
Around the Web
Comments
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved
> >